Antibiotic showdown: which drug works best for staph blood infection?
NCT ID NCT03248063
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compared two antibiotics, cloxacillin and cefazolin, in 315 adults with a serious bloodstream infection caused by methicillin-susceptible Staphylococcus aureus (MSSA). The goal was to see if cefazolin works as well as cloxacillin, the standard treatment, while potentially having fewer side effects and being easier to use. The main measure of success was a combination of survival, clearing the infection, and no relapse at 90 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cloxacillin and cefazolin (antibiotics)
- What this could lead to
- If cefazolin works as well as cloxacillin, doctors may have a safer, more reliable option for treating this serious bloodstream infection.
- What could go wrong
- This is a completed trial, so results are available. However, the study is relatively small (315 participants) and open-label, which can introduce bias. The findings may not apply to all patient groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BACTEREMIA DUE TO METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
François-Xavier Lescure
Paris, 75018, France